Literature DB >> 8435688

Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation.

K F Berman1, A R Doran, D Pickar, D R Weinberger.   

Abstract

To test the hypothesis that depressed and schizophrenic patients have a common pathophysiological mechanism for hypofunction of the prefrontal cortex ('hypofrontality'), we measured regional cortical blood flow (rCBF) in ten depressed patients, ten patients with schizophrenia, and 20 age- and sex-matched normal controls. Blood flow was measured during three different cognitive conditions: a resting state, a simple number-matching sensorimotor control task, and the Wisconsin Card Sorting test (WCS). The schizophrenic patients had lower prefrontal rCBF during the WCS. There were no differences in global or regional flow between the depressed patients and the normal subjects during any testing condition. Analysis of rCBF lateralisation showed that during the WCS normal subjects had relatively more left parietal blood flow than depressed patients, who had more right parietal blood flow. Since the testing condition that has most consistently revealed hypofrontality in schizophrenia (i.e. the WCS) was not associated with abnormal rCBF in the depressed patients, these data suggest that the pathophysiological mechanisms underlying prefrontal hypofunction in depression and schizophrenia are different.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435688     DOI: 10.1192/bjp.162.2.183

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  14 in total

Review 1.  [Executive functions in patients with depression. The role of prefrontal activation].

Authors:  N Vasic; R C Wolf; H Walter
Journal:  Nervenarzt       Date:  2007-06       Impact factor: 1.214

2.  Common and differential pathophysiological features accompany comparable cognitive impairments in medication-free patients with schizophrenia and in healthy aging subjects.

Authors:  Jean-Claude Dreher; Paul Koch; Philip Kohn; Jose Apud; Daniel R Weinberger; Karen Faith Berman
Journal:  Biol Psychiatry       Date:  2012-02-17       Impact factor: 13.382

3.  Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia.

Authors:  Helena Kyunghee Kim; Ana Cristina Andreazza; Pok Yik Yeung; Cameron Isaacs-Trepanier; L Trevor Young
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

4.  Clinical translation of neuroimaging research in mood disorders.

Authors:  Jakub Z Konarski; Roger S McIntyre; Joanna K Soczynska; Alexandra Bottas; Sidney H Kennedy
Journal:  Psychiatry (Edgmont)       Date:  2006-02

Review 5.  Biology and recent brain imaging studies in affective psychoses.

Authors:  P W Wang; T A Ketter
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 6.  Functional neuroimaging in psychiatry.

Authors:  C H Fu; P K McGuire
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-07-29       Impact factor: 6.237

7.  Alterations of white matter integrity in adults with major depressive disorder: a magnetic resonance imaging study.

Authors:  Ke Zou; Xiaoqi Huang; Tao Li; Qiyong Gong; Zhe Li; Luo Ou-yang; Wei Deng; Qin Chen; Chunxiao Li; Yi Ding; Xueli Sun
Journal:  J Psychiatry Neurosci       Date:  2008-11       Impact factor: 6.186

Review 8.  Executive function, neural circuitry, and genetic mechanisms in schizophrenia.

Authors:  Daniel Paul Eisenberg; Karen Faith Berman
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 9.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

Review 10.  Modelling prefrontal cortex deficits in schizophrenia: implications for treatment.

Authors:  J A Pratt; C Winchester; A Egerton; S M Cochran; B J Morris
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.